Table 2.
Response to CAPTEM treatment using RECIST parameters sorted by Tumor Characteristic.
| Tumor Characteristics | Radiographic Response, n (%) | ORR | DCR | ||||||
|---|---|---|---|---|---|---|---|---|---|
| n | CR | PR | SD | PD | n (%) | p Value | n (%) | p Value | |
| All patients | 116 | 1 (1) | 23 (20) | 61 (53) | 31 (27) | 24 (21) | 85 (73) | ||
| Primary Site (n = 116) | |||||||||
| pNEN | 47 | 1 (2) | 17 (36) | 18 (38) | 11 (23) | 18 (38) | 0.0001 | 36 (77) | 0.5049 |
| Non-pNEN | 69 | - | 6 (9) | 43 (62) | 20 (29) | 6 (9) | 49 (71) | ||
| Ki-67 (n = 106) * | |||||||||
| Ki-67 < 3% | 24 | - | 5 (21) | 17 (71) | 2 (8) | 5 (21) | 0.5241 | 22 (92) | 0.0084 |
| Ki-67 3–20% | 50 | 1 (2) | 12 (24) | 24 (48) | 13 (26) | 13 (26) | 37 (74) | ||
| Ki-67 20–55% | 26 | - | 3 (12) | 12 (46) | 11 (42) | 3 (12) | 15 (58) | ||
| Ki-67 > 55% | 6 | - | 1 (17) | 1 (17) | 3 (50) | 1 (17) | 2 (33) | ||
| Prior Treatments (n = 109) | |||||||||
| No SSA | 58 | 0 (0) | 12 (21) | 32 (55) | 14 (24) | 12 (21) | 0.6877 | 44 (76) | 0.6928 |
| SSA | 51 | 1 (2) | 8 (16) | 28 (55) | 14 (27) | 9 (18) | 37 (73) | ||
| No Surgery | 47 | 0 (0) | 11 (23) | 22 (47) | 15 (32) | 11 (23) | 0.6487 | 33 (70) | 0.2195 |
| Surgery | 62 | 1 (2) | 11 (18) | 37 (60) | 13 (21) | 12 (19) | 49 (79) | ||
| No Chemotherapy | 75 | 1 (1) | 14 (19) | 45 (60) | 15 (20) | 15 (20) | 0.6020 | 60 (80) | 0.0666 |
| Chemotherapy | 34 | 0 (0) | 6 (18) | 17 (50) | 1 (3) | 6 (18) | 23 (68) | ||
| No Targeted Therapy | 91 | 1 (1) | 16 (18) | 52 (57) | 22 (24) | 17 (19) | 0.8400 | 69 (76) | 0.7463 |
| Targeted Therapy | 18 | 0 (0) | 3 (17) | 10 (56) | 5 (28) | 3 (17) | 13 (72) | ||
| No PRRT | 106 | 1 (1) | 20 (19) | 58 (55) | 27 (25) | 21 (19) | 0.3909 | 79 (75) | 0.3135 |
| PRRT | 3 | 0 (0) | 0 (0) | 3 (100) | 0 (0) | 0 (0) | 3 (100) | ||
Shown is the frequency of each type of response per RECIST 1.1 per tumor characteristic and prior treatment. Abbreviations: CAPTEM, capecitabine and temozolomide; SSA, somatostatin analog; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, overall response rate; DCR, disease control rate; PRRT, peptide receptor radionucleotide therapy. * Ki-67 unknown (n = 10).